Passage Bio Q2 net loss narrows 16.67% to $7.82 million
Reuters2026/08/10 11:17- Passage Bio posted a net loss of $7.82 million, narrowing from $9.39 million a year earlier; operating loss improved to $8.27 million.
- R&D expense fell 42.51% to $3.34 million; general and administrative costs rose 52.06% to $6.87 million.
- Other income dropped 52.48% to $451,000; results included a $1.94 million net gain on lease terminations.
- Cash and cash equivalents totaled $24.2 million as of June 30, 2026, with management flagging substantial doubt about going-concern status.
- Company is winding down gene-therapy programs, terminated key Catalent and Gemma arrangements, and expects its Remix merger to close in Q4 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Storage Giant Offers Huge Bonuses Again: Micron Awards Up to 68 Months’ Bonus
Micron Technology has announced record-breaking bonuses for its employees in Taiwan, ranging from 35 to 68 months’ salary, with a minimum cash compensation of 1.7 million New Taiwan dollars. However, the Taoyuan union, representing about two-thirds of Micron’s workers in Taiwan, has refused to accept the offer, insisting that 15% of operating profits be included in the bonus distribution and maintaining the threat of a strike.
Dogecoin ETF Closure Sets October Exit for Bitwise BWOW Holders
Crypto prices
More
